Embla Medical

Embla Medical benefits from the latest reported quarter's 7% organic sales growth in prosthetics and neuro-orthotics because its exposure is strongest in that segment.

The global prosthetics and orthotics market reached USD 6.8 billion in 2025 and is forecast to hit USD 9.5 billion by 2033, a 4.2% CAGR over 2026 to 2033. Ottobock's business centers on prosthetics, orthotics, and mobility solutions. Most health care systems worldwide do not treat health-economic studies as a standard element of prosthetics and orthotics coverage decisions.

Patient-care integration is the clearest near-term execution risk for Embla Medical, while its reimbursement-dependent sales model adds exposure to payer decisions. Embla Medical reported that significant integration effort slowed its ability to increase patient volumes in selected regions. Patient Care recorded 0% organic sales growth, compared with 7% for Prosthetics & Neuro Orthotics and 2% for Bracing & Supports.

Around 90% of Embla Medical's product sales and services are estimated to be reimbursed by a third party.

Patient Care revenue that recurs supports revenue continuity, but customer-level contribution cannot be assessed without a defined customer unit and delivery costs. Embla Medical reports 70-80% of Patient Care revenue as recurring.

Embla Medical estimates around 90% of product sales and services receive third-party reimbursement. The firm primarily distributes products via its own direct sales network.

Embla Medical's offering pairs mobility devices with direct patient care instead of supplying hardware alone. The company develops, manufactures and distributes prosthetic, neuro orthotic and bracing and supports solutions, and serves patients at its care facilities across the globe.

Products reach users through healthcare providers that specialize in mobility impairment. The company relies largely on its own direct sales network to sell products and operates in around 40 countries.